{"id":1021314,"date":"2026-11-16T09:18:13","date_gmt":"2026-11-16T14:18:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/"},"modified":"2026-11-16T09:18:13","modified_gmt":"2026-11-16T14:18:13","slug":"erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/","title":{"rendered":"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HLrY8EzNjQbPf4EhcuAm83qbZHPuskQlZnoz2DKhNOHXtLEFqk0FJEgOjbNyGlhk1WVkRfKe15ZIEMWY1glSNA==\" rel=\"nofollow\" target=\"_blank\">Erasca, Inc.<\/a> (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS\/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates.<\/p>\n<p>The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18\u201320 in Barcelona, Spain.<\/p>\n<p>To register, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0gRw9rnolgb1GnoeKk9T9avzVSmFHknXi1wATDKbe7i_oVSaDrfRcFo8gbr__aIEvWJjWESoDe01uVAlVfW8SmPNmWSFIZYYZgFoUWxJKzI=\" rel=\"nofollow\" target=\"_blank\">click here<\/a>. A live question and answer session will follow the formal presentations. A live webcast of the event will be available online at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HLrY8EzNjQbPf4EhcuAm8_eBBEFQVwE4Gd0K3SIneIH6zm1QhdykXi7FIn3ETw4jZkj8KFMsU3fxrOBgzjgImjpgN-1XDCCrxYr-EYxmA6vjV3SIO47sgoWuvxpJwxXgtmsEliTaHlQc9xkklowOmbqZlWCFU0MpINpsqovsA8fyvxrHKNO-aILguBdP_mCK8aCGcz3KaO6iqxEBRylvA9rCYWgH9ZdtLhvCaqlxGN2Z2ZTO8djKbGWwBNIAbfT1cYuXUdy5fJ3xdEjHlasHHFQQPqP_jlLyan4dBRbXd85KUCvY44dJV3GEcCoxTRX5imrTG84s3bjoJQztqZfUXOBBRzsyOneipEFRzdAWVjjawg35xEk_nTOuUk5xjwwpI3rQVTnZdGasNCe8dUBkLDxJ13eONrG-LRbbuOp-oGYQ3-56HVNsb0bHIx2pY36h_Kw0tpAmc2ZF22p6h5yAXLOtwQ2Oulgwp8ydJ18SDnVPFohncD6IkKAuvk0X1cmwHZKPJl9jnfgVmJg92Mileg==\" rel=\"nofollow\" target=\"_blank\">Erasca.com\/events<\/a>. An archived replay of the event will be available for 30 days following the webcast at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HLrY8EzNjQbPf4EhcuAm8_9KGfgoHgGj_MeEdxQhON0uxpUoax-OG0X9M2piwcTYRBQeMnvBERr5NkFoLN_wUZ2kpByuLw-7NT95WnkQZnSw7qU1-pbyNomg8IjcA7PuiS65Paj6iSGyfqzsXinr1wK_zgNN0tr8ORSuOt9qCqpSF7ZEs82aRYdVSO3z4T7jm5VrIEL2lVoWupX1-UOb3C-ICwVbNDUDPxVfFh4lQboyq1WkKocqPlfQrh5oHcyceR_csVdQu4ajDPjxfIXC6sl2wr8rgO0-TTxOkqFga-DWgKKE03IlJCMKi6KgNonVx1rfOqpMbX7SXG4A9XtZ2Rm5w7u5MGMasoFfhxoeLErYP3oWtDQ7L-NWQt_GeDMbaxK6K_mBdBnjZY72JaoRpgpuxYFp3GfOltN7r74ZHhvklnrrRR3_KpSRuKKhTN611Vk8UINzkX0KnFbeo0w00UNuX1ovga7HSm3hrmBSuDQ6WphnDU8QTGHMUaDu4ARdQbaqj-QKe1ZCRpux6DTsqA==\" rel=\"nofollow\" target=\"_blank\">Erasca.com\/events<\/a>.<\/p>\n<p>\n        <strong>About ERAS-0015<\/strong><br \/>\n        <br \/>ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. Early dose escalation data in AURORAS-1 demonstrated favorable safety and tolerability results, well-behaved, linear PK, and confirmed and unconfirmed partial responses in multiple patients across multiple tumor types with different RAS mutations, including confirmed partial responses at doses as low as 8 mg once daily (QD). ERAS-0015 is also designed to prevent resistance against mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties in multiple animal species.<\/p>\n<p>\n        <strong>About ERAS-4001<\/strong><br \/>\n        <br \/>ERAS-4001 is an investigational, oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile. Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors. ERAS-4001 demonstrated favorable preclinical in vitro potency against KRAS G12X mutations as well as KRAS wildtype amplifications, which may limit treatment resistance mediated through KRAS wildtype activation. No activity was observed for ERAS-4001 against HRAS or NRAS wildtype proteins in preclinical studies, which may enable a better therapeutic window compared to pan-RAS inhibitors. ERAS-4001 showed potent activity against both GTP-bound (active state) and GDP-bound (inactive state) KRAS with single digit nanomolar IC50s. In vivo, ERAS-4001 induced tumor regression in multiple KRAS-mutant models. In preclinical studies, ERAS-4001 showed encouraging ADME and PK properties.<\/p>\n<p>\n        <strong>About Erasca<\/strong><br \/>\n        <br \/>At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS\/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS\/MAPK pathway for the treatment of patients with cancer. We believe our team\u2019s capabilities and experience, further guided by our scientific advisory board which includes the world\u2019s leading experts in the RAS\/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>Erasca\u00a0cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-0015 and ERAS-4001; statements regarding ERAS-0015\u2019s clinical data, including its potential activity at low doses and across multiple tumor types with different RAS mutations; and statements regarding ERAS-0015\u2019s preclinical data. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in our business described in our prior filings with the SEC, including under the heading \u201cRisk Factors\u201d in our annual report on Form 10-K for the year ended December 31, 2025, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors, LLC<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sbKLqlHUXiYBVGyjokZYsgZTd62ZuiVoNfjSE8cpfz6HuoKdcDaHWPU_9kp1bXibKgVd3lbb5IvxBWILGscg8JeEBvEKs0HWRZynDXvuTnV2I7jh_v69jf_g5Pdusnf7\" rel=\"nofollow\" target=\"_blank\">jallaire@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Michael Fitzhugh<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T_rLGswKVkJ1DOI1WaAPiLtu516Newd0gDcbGUrqrVCzsMjgA87nfExSnP5vjH_p97MI7-hLS6g8r5o_i0eI6wSaRIwanhAv87ClQeuZd3ZPpbZkV5YEAX-DaNI7jezy\" rel=\"nofollow\" target=\"_blank\">mfitzhugh@lifescicomms.com<\/a><\/p>\n<p>Source: Erasca, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTRlYTJlMWYtMzUyMC00NzQ2LWJiZTgtZjMxM2QyNzAyOGJkLTUwMDA5ODYzNC0yMDI2LTExLTE2LWVu\/tiny\/Erasca-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS\/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates. The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18\u201320 in Barcelona, Spain. To register, click here. A live question and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021314","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS\/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates. The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18\u201320 in Barcelona, Spain. To register, click here. A live question and &hellip; Continue reading &quot;Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T14:18:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise\",\"datePublished\":\"2026-11-16T14:18:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/\"},\"wordCount\":763,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/\",\"name\":\"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==\",\"datePublished\":\"2026-11-16T14:18:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/","og_locale":"en_US","og_type":"article","og_title":"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise - Market Newsdesk","og_description":"SAN DIEGO, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS\/MAPK pathway-driven cancers, today announced that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates. The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18\u201320 in Barcelona, Spain. To register, click here. A live question and &hellip; Continue reading \"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-16T14:18:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise","datePublished":"2026-11-16T14:18:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/"},"wordCount":763,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/","name":"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==","datePublished":"2026-11-16T14:18:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NzkxMyM3OTY2Njk4IzUwMDA5ODYzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/erasca-to-host-virtual-investor-event-highlighting-clinical-momentum-across-its-ras-targeting-franchise\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021314"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021314\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}